July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Investigation of the number of intravitreal injections of the anti-VEGF agent using OCT angiography for macular edema due to retinal vein branch occlusion.
Author Affiliations & Notes
  • RYO TOMITA
    ophthalmology, Nagoya University, Nagoya, Japan
  • Takeshi Iwase
    ophthalmology, Nagoya University, Nagoya, Japan
  • Yasunobu Ogasawara
    ophthalmology, Nagoya University, Nagoya, Japan
  • Shunichi Suwa
    ophthalmology, Nagoya University, Nagoya, Japan
  • Hiroko Terasaki
    ophthalmology, Nagoya University, Nagoya, Japan
  • Footnotes
    Commercial Relationships   RYO TOMITA, None; Takeshi Iwase, None; Yasunobu Ogasawara, None; Shunichi Suwa, None; Hiroko Terasaki, Alcon Japan (R), Alcon Japan (F), Allergan Japan (F), Bayer Yakuhin (R), Carl Zeiss (R), Carl Zeiss (F), HOYA (F), KOWA PHARMACEUTICAL (F), NIDEK (F), Novartis Pharma (R), Novartis Pharma (F), Otsuka Pharmaceutical (F), Pfizer Inc (F), Santen Pharmaceutical (R), Santen Pharmaceutical (F), SENJU PHARMACEUTICAL (F), Wakamoto Pharmaceutical (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4053. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      RYO TOMITA, Takeshi Iwase, Yasunobu Ogasawara, Shunichi Suwa, Hiroko Terasaki; Investigation of the number of intravitreal injections of the anti-VEGF agent using OCT angiography for macular edema due to retinal vein branch occlusion.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4053.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the number of intravitreal injections(IVI) of the anti-vascular endothelial growth factor(VEGF) agents using vascular density determined by OCT-Angiography(OCTA) for macular edema secondary to branch retinal vein occlusion(BRVO).

Methods : In this retrospective study, we reviewed the medical records of the 29 eyes of 29 patients(66.7±11.5) with macular edema secondary to BRVO treated with the IVI of anti-VEGF agents at Nagoya University Hospital. The patients underwent OCTA(Angio Plex) examination when the macular edema was resolved 1 month after the first IVI. They were followed at least until 6 months after the first IVI. On the OCTA image, we divided it into two hemispheres with a horizontal line including fovea, i.e. the affected hemisphere by BRVO or the unaffected hemisphere. Then, we measured the vessel density using embedded soft ware on the area where it was most decreased on affected hemisphere as the affected vessel density(AVD) and measured it on the symmetrical position to AVD area to the horizontal line as the unaffected vessel density(UVD). The vessel density reduction rate(VDR rate) (%) was defined as following formula: VDR rate(%) = (1–AVD/UVD) × 100. The IVI of the anti-VEGF were performed pro re nata regimen. We examined the relationship between the number of IVI until 6 months after from the first IVI and other factors including the retinal VDR rate, the central foveal thickness before the first IVI, the visual acuity, and the history of hypertension.

Results : Sixteen patients had multiple IVI due to the recurrence of macular edema(recurrence group) and 13 patients were not re-injected(resolved group). The VDR rate was significantly higher in the resolved group(36±29%) than in the recurrence group(18±18%) (p<0.05). There was no significant difference in the other factors. The total number of IVI was significantly negatively correlated with the VDR rate(r=-0.421, p<0.05). Multiple regression analysis showed that the VDR rate(p<0.05) and the history of hypertension(p<0.05) were independent factors significantly correlated with the total number of IVI.

Conclusions : The VDR rate one month after the initial IVI was correlated with the total number of IVI until 6 months after the occurrence of BRVO, suggesting that the VDR rate would be useful index for predicting the frequency of anti-VEGF IVI.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×